Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten - PubMed (original) (raw)
Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten
Marlies E H M Van Hoef. Haematologica. 2013 Apr.
No abstract available
Comment in
- Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten.
Bucher CM, Passweg J. Bucher CM, et al. Haematologica. 2013 Apr;98(4):e48. doi: 10.3324/haematol.2013.083584. Haematologica. 2013. PMID: 23543156 Free PMC article. No abstract available.
Similar articles
- Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten.
Bucher CM, Passweg J. Bucher CM, et al. Haematologica. 2013 Apr;98(4):e48. doi: 10.3324/haematol.2013.083584. Haematologica. 2013. PMID: 23543156 Free PMC article. No abstract available. - Rituximab for prevention and treatment of graft-versus-host disease.
Kharfan-Dabaja MA, Cutler CS. Kharfan-Dabaja MA, et al. Int J Hematol. 2011 May;93(5):578-585. doi: 10.1007/s12185-011-0855-2. Epub 2011 May 7. Int J Hematol. 2011. PMID: 21547615 Review. - Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Kennedy VE, Savani BN, Greer JP, Kassim AA, Engelhardt BG, Goodman SA, Sengsayadeth S, Chinratanalab W, Jagasia M. Kennedy VE, et al. Biol Blood Marrow Transplant. 2016 Oct;22(10):1801-1807. doi: 10.1016/j.bbmt.2016.06.029. Epub 2016 Jul 1. Biol Blood Marrow Transplant. 2016. PMID: 27377900 - GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.
Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA. Parody R, et al. Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. Bone Marrow Transplant. 2016. PMID: 27295268 No abstract available.
Cited by
- Graft-versus-host disease affecting oral cavity. A review.
Margaix-Muñoz M, Bagán JV, Jiménez Y, Sarrión MG, Poveda-Roda R. Margaix-Muñoz M, et al. J Clin Exp Dent. 2015 Feb 1;7(1):e138-45. doi: 10.4317/jced.51975. eCollection 2015 Feb. J Clin Exp Dent. 2015. PMID: 25810826 Free PMC article. Review. - Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.
Johnston HF, Xu Y, Racine JJ, Cassady K, Ni X, Wu T, Chan A, Forman S, Zeng D. Johnston HF, et al. Biol Blood Marrow Transplant. 2014 Aug;20(8):1089-103. doi: 10.1016/j.bbmt.2014.04.028. Epub 2014 May 4. Biol Blood Marrow Transplant. 2014. PMID: 24796279 Free PMC article. - Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten.
Bucher CM, Passweg J. Bucher CM, et al. Haematologica. 2013 Apr;98(4):e48. doi: 10.3324/haematol.2013.083584. Haematologica. 2013. PMID: 23543156 Free PMC article. No abstract available.
References
- Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host-disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-11 - PubMed
- Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft versus host disease. Blood. 2004;104(8):2603-6 - PubMed
- Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory scleroderma-tous chronic graft versus host disease. Leukemia 2006;20(1):172-3 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources